Sicras-Mainar, A., Rejas, J., Navarro-Artieda, R., Aguado-Jodar, A., Ruiz-Torrejón, A., Ibáñez-Nolla, J., & Kvasz, M. (2013). Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain. BioMed Central.

Sicras-Mainar, Antoni, Javier Rejas, Ruth Navarro-Artieda, Alba Aguado-Jodar, Amador Ruiz-Torrejón, Jordi Ibáñez-Nolla, and Marion Kvasz. Health Economics Perspective of Fesoterodine, Tolterodine or Solifenacin As First-time Therapy for Overactive Bladder Syndrome in the Primary Care Setting in Spain. BioMed Central, 2013.

Sicras-Mainar, Antoni, et al. Health Economics Perspective of Fesoterodine, Tolterodine or Solifenacin As First-time Therapy for Overactive Bladder Syndrome in the Primary Care Setting in Spain. BioMed Central, 2013.